Evaluation of pharmacodynamics and safety of teneligliptin in type 2 diabetic patients with chronic renal dysfunction

Trial Profile

Evaluation of pharmacodynamics and safety of teneligliptin in type 2 diabetic patients with chronic renal dysfunction

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Teneligliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 31 Mar 2015 Status changed from recruiting to completed, as reported by University Hospital Medical Information Network - Japan record.
    • 03 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top